Compare Stocks

→ The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEM Hemostemix	C$0.05 -10.0%	C$0.07	C$0.04 ▼ C$0.18	C$4.04M	0.55	41,030 shs	82,500 shs
SNG Silver Range Resources	C$0.10 +11.8%	C$0.08	C$0.06 ▼ C$0.15	C$9.02M	-0.03	30,953 shs	1,500 shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEM Hemostemix	0.00%	-9.09%	-23.08%	-33.33%	-70.59%
SNG Silver Range Resources	0.00%	+5.56%	+35.71%	+46.15%	-29.63%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

The "Smart Money" Is Ready for May 1st Are You? (Ad)

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNG Silver Range Resources	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEM Hemostemix	N/A	N/A	N/A	N/A
SNG Silver Range Resources	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEM Hemostemix	N/A	N/A	C$0.00 per share	10.77	C($0.08) per share	N/A
SNG Silver Range Resources	N/A	N/A	C$0.01 per share	16.25	C$0.11 per share	N/A
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEM Hemostemix	-C$3.17M	-C$0.04	N/A	∞	N/A	N/A	N/A	-165.67%	4/25/2024 (Estimated)
SNG Silver Range Resources	-C$1.69M	-C$0.02	N/A	∞	N/A	N/A	-16.23%	-9.12%	5/2/2024 (Estimated)
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A
SNG Silver Range Resources	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEM Hemostemix	N/A	0.25	0.48
SNG Silver Range Resources	0.07	5.82	7.93
TRIL Trillium Therapeutics	N/A	19.82	19.82

Ownership

Institutional Ownership

Company	Institutional Ownership
HEM Hemostemix	N/A
SNG Silver Range Resources	N/A
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
HEM Hemostemix	12.15%
SNG Silver Range Resources	38.33%
TRIL Trillium Therapeutics	9.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HEM Hemostemix	N/A	89.79 million	N/A	Not Optionable
SNG Silver Range Resources	N/A	94.97 million	N/A	Not Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

TRIL, ANR, REDX, SNG, and HEM Headlines

Source	Headline
	Cachet Bicycle shakes off COVID baytoday.ca - February 25 at 12:23 PM
	Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics chch.com - January 30 at 5:32 PM
	TTI apprehends motorists for illegal removal of clamps, hunt for four others underway bulawayo24.com - January 30 at 5:32 PM
	BridgeBio raises $1.25bn, and other biotech financings pharmaphorum.com - January 19 at 7:18 AM
	Ratio Therapeutics Raises $50M in Series B Financing precisionmedicineonline.com - January 17 at 1:39 PM
	Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com businesswire.com - November 10 at 1:22 PM
	Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions benzinga.com - November 8 at 1:30 AM
	The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period uk.finance.yahoo.com - July 31 at 9:03 AM
	Ratio Therapeutics unveils new research and development facility biopharma-reporter.com - May 15 at 10:33 AM
	WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death' msn.com - April 26 at 12:18 AM
	Leukemia Therapeutics Global Market Report 2023 uk.finance.yahoo.com - April 4 at 10:35 AM
	Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck finance.yahoo.com - March 28 at 9:12 AM
	Trillium House, an affordable housing project in Warrenton, close to completion dailyastorian.com - January 10 at 12:26 AM
	FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma nz.finance.yahoo.com - October 19 at 9:39 AM
	Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment seekingalpha.com - September 14 at 9:48 AM
	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors nz.finance.yahoo.com - September 12 at 7:55 AM
	Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed seekingalpha.com - August 17 at 11:07 AM
	TTI reviews parking model chronicle.co.zw - August 10 at 10:41 PM
	TTI working round the clock to configure its systems chronicle.co.zw - August 10 at 10:41 PM
	Pfizer in advanced talks to buy firm making sickle cell drugs pmnewsnigeria.com - August 7 at 3:57 AM
	10 Psychedelics CEOs To Pay Attention To In 2022 markets.businessinsider.com - June 22 at 10:08 AM
	Highlights from ASCO Annual Meeting 2022 healio.com - June 15 at 1:37 PM
	Chlormethine gel may be more effective than ointment for mycosis fungoides healio.com - May 27 at 4:34 PM
	Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling? edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Hemostemix

CVE:HEM

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Silver Range Resources

CVE:SNG

Silver Range Resources Ltd., a junior resource exploration company, engages in the acquisition, exploration, and evaluation of precious metal resources in Canada. The company explores for gold, silver, zinc, lead, and copper deposits. Its property portfolio comprises mineral properties located in Nevada, the Northwest Territories, Nunavut, and the Yukon Territory. Silver Range Resources Ltd. was incorporated in 2010 and is headquartered in Vancouver, Canada.

Trillium Therapeutics

NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial